Edition:
United States

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

30.05USD
10:54am EDT
Change (% chg)

$-0.12 (-0.41%)
Prev Close
$30.17
Open
$30.31
Day's High
$30.60
Day's Low
$30.02
Volume
2,126
Avg. Vol
31,804
52-wk High
$39.67
52-wk Low
$20.27

Latest Key Developments (Source: Significant Developments)

FDA Grants Rare Pediatric Disease Designation To A4250
Tuesday, 12 Jun 2018 08:30am EDT 

June 12 (Reuters) - Albireo Pharma Inc ::FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION TO A4250; ALBIREO ELIGIBLE TO APPLY FOR PRIORITY REVIEW VOUCHER.  Full Article

Albireo Qtrly Net Loss Per Share - Basic And Diluted $0.15
Thursday, 17 May 2018 07:30am EDT 

May 17 (Reuters) - Albireo Pharma Inc ::ALBIREO PROVIDES FIRST QUARTER 2018 BUSINESS UPDATE.ALBIREO PHARMA INC - QTRLY NET LOSS PER SHARE - BASIC AND DILUTED $0.15.  Full Article

Albireo Pharma Inc Files For Non-Timely 10-K ‍​
Monday, 19 Mar 2018 11:40am EDT 

March 19 (Reuters) - Albireo Pharma Inc ::ALBIREO PHARMA INC FILES FOR NON-TIMELY 10-K WITH THE U.S. SEC ‍​.  Full Article

Albireo Reports Fourth Quarter And Year-End 2017 Financial Results
Thursday, 15 Mar 2018 07:30am EDT 

March 15 (Reuters) - Albireo Pharma Inc ::ALBIREO REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS.ALBIREO PHARMA INC - ABOUT $200 MILLION CURRENT CASH BALANCE EXPECTED TO BE SUFFICIENT TO FUND OPERATIONS INTO 2021.ALBIREO PHARMA INC - PHASE 3 PFIC TRIAL OF IBAT INHIBITOR A4250 PLANNED TO INITIATE IN SPRING 2018.  Full Article

Albireo Prices $65.0 Mln Public Offering Of Common Stock
Thursday, 25 Jan 2018 08:45am EST 

Jan 25 (Reuters) - Albireo Pharma Inc ::ALBIREO PRICES $65.0 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 1.97 MILLION COMMON SHARES PRICED AT $33.00PER SHARE.  Full Article

Albireo Announces Agreement With Healthcare Royalty Partners
Wednesday, 3 Jan 2018 08:00am EST 

Jan 3 (Reuters) - Albireo Pharma Inc ::ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN.ALBIREO PHARMA INC - ‍ALBIREO SUBSIDIARY ELIGIBLE TO RECEIVE UP TO $60 MILLION UNDER AGREEMENT​.ALBIREO PHARMA INC - ‍DECISION ON JAPANESE NEW DRUG APPLICATION FOR ELOBIXIBAT EXPECTED IN FIRST HALF OF 2018​.ALBIREO PHARMA -HCR OBTAINS RIGHT TO RECEIVE ROYALTIES, SALES MILESTONES FOR ELOBIXIBAT IN JAPAN THAT MAY BE PAYABLE BY EA PHARMA, UP TO A THRESHOLD​.ALBIREO PHARMA INC - ‍ELOBIX HAS RETAINED ITS RIGHT TO RECEIVE A MILESTONE PAYMENT FROM EA PHARMA IF ELOBIXIBAT IS APPROVED BY MHLW​.ALBIREO PHARMA INC - ‍ IF SPECIFIED THRESHOLD IS REACHED, ELOBIX WILL AGAIN BECOME ELIGIBLE TO RECEIVE ROYALTIES AND SALES MILESTONES FOR ELOBIXIBAT.  Full Article

Albireo posts Q3 loss per share $0.73‍​
Tuesday, 14 Nov 2017 08:00am EST 

Nov 14 (Reuters) - Albireo Pharma Inc :Albireo reports third quarter 2017 financial results.Albireo Pharma Inc - ‍decision on potential approval of elobixibat in Japan expected in first half of 2018​.Albireo Pharma Inc - ‍revenue totaled $0 for Q3 of 2017 compared with $28,000 for Q3 of 2016​.Albireo Pharma Inc - qtrly loss per share $0.73‍​.Albireo Pharma - ‍expects current cash resources will meet operating requirements till end of 2019, assuming receipt of payment from EA Pharma in 2018​.  Full Article

Albireo Pharma files for mixed shelf of up to $125 million‍​
Friday, 13 Oct 2017 05:43pm EDT 

Oct 13 (Reuters) - Albireo Pharma Inc :Albireo Pharma Inc files for mixed shelf of up to $125 million - SEC filing‍​ ‍​.  Full Article

EMA paediatric committee agrees to Albireo's A4250 pediatric investigation plan
Tuesday, 26 Sep 2017 08:00am EDT 

Sept 26 (Reuters) - Albireo Pharma Inc ::EMA's paediatric committee agrees to Albireo’s a4250 pediatric investigation plan.Albireo Pharma - ‍completion of pip would provide an additional two years of market exclusivity​.Albireo Pharma - ‍plan to initiate our previously announced phase 3 trial of A4250 by year end​.Albireo Pharma - pdco of EMA agreed to pediatric investigation plan for lead product candidate a4250 in patients with pfic.Albireo Pharma Inc - ‍completion of agreed pip would provide an additional two years of market exclusivity in EU, making a total of 12 years​.  Full Article

Albireo Pharma Q2 loss per share $0.86
Monday, 21 Aug 2017 08:36am EDT 

Aug 21 (Reuters) - Albireo Pharma Inc :Albireo reports second quarter 2017 financial results.Albireo Pharma Inc - qtrly net loss per share diluted $0.86.Q2 earnings per share view $-0.85 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Albireo Qtrly Net Loss Per Share - Basic And Diluted $0.15

* ALBIREO PHARMA INC - QTRLY NET LOSS PER SHARE - BASIC AND DILUTED $0.15 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)